Prothena Corporation plc
PRTA
NASDAQ·Healthcare·Biotechnology·Mkt cap $514.1M
$9.82
▲ +2.29%
P/E
-3.55
Mkt Cap
$514.1M
52-Wk Range
$7.73–$11.80
52-Week Range
$7.73 - $11.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Strategic partnerships with Roche and Bristol-Myers Squibb providing development and commercialization support
- Specialized expertise in protein misfolding diseases and antibody therapeutics
- Advanced clinical pipeline with multiple late-stage candidates reducing development risk
Bear Case
2 risks
- Low volatility (beta -0.3).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Potential FDA approvals and commercialization of Birtamimab for AL amyloidosis
Value
Extreme premium - high expectations embedded
Momentum
Strong
+14.7% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PRTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.32 vs -$0.39 consensus (+17.9% surprise). Revenue of $1.0M vs $421.7K expected (+139.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+17.9%
Revenue trend · last 8Q
—
—
+572%
—
-97%
+149%
+2306%
-77%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q1 26
Q2 26
$132.0M
$970.0K
$2.1M
$2.8M
$4.4M
$2.4M
$51.1M
$1.0M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-1839.9%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 24, 2026
vs Industry
How PRTA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related